Lee Chan Henry 4

What Happened
Lee Chan Henry, Senior Vice President and General Counsel of BeOne Medicines (ONC), received two awards on 2026-03-06 totaling 95,264 performance share units (PSUs): 65,390 PSUs and 29,874 PSUs. Each award is reported at an acquisition price of $0.00 (no cash paid). These are awards/grants (not open-market purchases or sales).

Key Details

• Transaction date: 2026-03-06; Form 4 filed 2026-03-10 (check SEC record for timeliness codes).
• Awards: 65,390 shares @ $0.00 (footnote F1); 29,874 shares @ $0.00 (footnote F2). Total = 95,264 underlying ordinary shares.
• Vesting: F1 PSUs vest in 2027; F2 PSUs vest in 2028, each subject to continued service through the vesting date.
• Accelerated vesting: Unvested securities are subject to accelerated vesting upon certain termination events (as noted in the filing).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.

Context
These awards are compensation in the form of performance-based restricted stock units that only convert to ordinary shares if vesting conditions are met; they are not immediate market purchases or sales. The filing reports $0 as the acquisition price; the actual economic value will depend on ONC’s share price at the time any units vest or are settled. Such grants are common executive compensation and do not, by themselves, indicate a near-term buy/sell signal.